EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

A Necroptosis‐Related Seven‐Gene Risk Score Stratifies Prognosis and Predicts Immunotherapy Response and EGFR ‐ TKI Sensitivity in Lung Adenocarcinoma

Xinkui Xiong iD, Chen Chen, Mingzhi Zhang, Derong Tang, Qingquan Wu, Jianqiang Zhao, Bao Zang, Zhiyun Xu iD

Cancer Medicine · 2026-11 · 15 (11)

DOI: 10.1002/cam4.72511 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 15.11.2026. Verfasst von Xinkui Xiong und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, The Affiliated Huai'an No. 1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu, China. Hauptthemen laut MEDLINE: Necroptosis, Lung Neoplasms, Adenocarcinoma of Lung, Immunotherapy. Die Arbeit nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Nanjing Medical University Science and Technology Development Fund, Jiangsu Provincial Medical Key Discipline Cultivation Unit.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Necroptosis is a regulated form of inflammatory cell death with context‐dependent roles in tumor progression and immune regulation. However, the prognostic value and therapeutic implications of necroptosis‐related transcriptional programs in lung adenocarcinoma (LUAD) remain incompletely defined.

Methods

Transcriptomic profiles and clinical data for LUAD were obtained from TCGA and multiple GEO cohorts. Differentially expressed necroptosis‐related genes were used to construct a prognostic model via LASSO‐Cox regression, generating a necroptosis‐related risk score (NRRS). Prognostic performance was evaluated by Kaplan–Meier analysis, time‐dependent ROC curves, and multivariable Cox regression. A nomogram integrating NRRS and clinicopathological variables was developed and assessed by calibration and decision curve analysis. Functional enrichment, somatic mutations, tumor mutational burden (TMB), and neoantigen load were compared between NRRS strata. The tumor immune microenvironment was evaluated using ESTIMATE, ssGSEA, immune checkpoint analyses, and Immunophenoscore (IPS), with validation in independent immunotherapy cohorts. EGFR‐TKI vulnerability was explored using pharmacogenomic prediction, external clinical datasets, CCLE analyses, and necroptosis inhibition assays in EGFR‐mutant LUAD models.

Results

A seven‐gene NRRS consistently stratified LUAD patients into high‐ and low‐risk groups with significantly different survival across TCGA and GEO cohorts. NRRS remained an independent prognostic factor, and the NRRS‐based nomogram improved individualized survival prediction. NRRS‐high tumors were enriched for proliferative and genome‐instability pathways, showed distinct mutation patterns, and had higher TMB/neoantigen load. Despite increased genomic immunogenicity markers, NRRS‐high tumors displayed immune‐depleted features, whereas NRRS‐low tumors had higher immune infiltration, more favorable IPS profiles, and improved outcomes in immunotherapy validation cohorts. Higher NRRS was also associated with greater predicted sensitivity and clinical benefit from EGFR‐TKIs, and necroptosis inhibition attenuated EGFR‐TKI cytotoxicity in EGFR‐mutant LUAD models.

Conclusions

NRRS may be associated with EGFR‐TKI vulnerability, immune microenvironment features, and potential immunotherapy responsiveness in LUAD. These exploratory results support further evaluation of NRRS as a candidate biomarker for therapeutic stratification.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NecroptosisLung NeoplasmsAdenocarcinoma of LungImmunotherapyProtein Kinase InhibitorsHumansPrognosisErbB ReceptorsTumor MicroenvironmentBiomarkers, TumorFemaleMaleNomogramsMutationRisk Assessment

Stichwörter der Autor:innen

EGFR tyrosine kinase inhibitorsgene signatureimmunotherapylung adenocarcinomanecroptosisprognostic modelprognostic signaturerisk scoretumor immune microenvironmenttumor mutational burden

Substanzen

ErbB ReceptorsProtein Kinase InhibitorsEGFR protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Thoracic Surgery, The Affiliated Huai'an No. 1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu, China.

ORCID-Profile: Xinkui Xiong, Zhiyun Xu

Förderung

  • Nanjing Medical University Science and Technology Development Fund
  • Jiangsu Provincial Medical Key Discipline Cultivation Unit

Zitieren

APA

Xiong, X., Chen, C., Zhang, M., Tang, D., Wu, Q., Zhao, J., Zang, B., & Xu, Z. (2026). A Necroptosis‐Related Seven‐Gene Risk Score Stratifies Prognosis and Predicts Immunotherapy Response and EGFR ‐ TKI Sensitivity in Lung Adenocarcinoma. Cancer Medicine, 15(11). https://doi.org/10.1002/cam4.72511

Vancouver

Xiong X, Chen C, Zhang M, Tang D, Wu Q, Zhao J, et al. A Necroptosis‐Related Seven‐Gene Risk Score Stratifies Prognosis and Predicts Immunotherapy Response and EGFR ‐ TKI Sensitivity in Lung Adenocarcinoma. Cancer Medicine. 2026;15(11). doi:10.1002/cam4.72511

BibTeX
@article{Xiong2026,
  author = {Xiong, Xinkui and Chen, Chen and Zhang, Mingzhi and Tang, Derong and Wu, Qingquan and Zhao, Jianqiang and Zang, Bao and Xu, Zhiyun},
  title = {A Necroptosis‐Related Seven‐Gene Risk Score Stratifies Prognosis and Predicts Immunotherapy Response and EGFR ‐ TKI Sensitivity in Lung Adenocarcinoma},
  journal = {Cancer Medicine},
  year = {2026},
  volume = {15},
  number = {11},
  doi = {10.1002/cam4.72511}
}
Kostenlos starten →